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PASS predictionAbstract Microwave assisted irradiation of resorcinol and substituted aryl aldehydes using sulfa-
mic acid as catalyst afforded novel 9-aryl-9H-xanthene-3,6-diol derivatives (1a–f) in good yields.
The newly synthesized compounds which were previously selected on the basis of PASS prediction
were tested for anti-inﬂammatory activity using carrageenan-induced rat paw edema and analgesic
activity using acetic acid induced writhing and formalin-induced paw edema in mice along with the
estimation of gastric ulcerogenicity index. Compounds 1e and 1f exhibited signiﬁcant anti-
inﬂammatory and analgesic activities as compared to standard drug. The study also revealed that
compounds (1a–f) showed minimum or no ulcerogenicity in mice as that of the standard drug.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Inﬂammation is a defensive but exaggerated local tissue reac-
tion in response to exogenous or endogenous insult. It is acomplex phenomenon, comprising of biochemical as well as
immunological factors. It is recognized by heat, redness, tumor
and pain. Traditionally most treatment of inﬂammation is with
non-steroidal anti-inﬂammatory drugs (NSAID’s). The most
important mechanism of anti-inﬂammatory action of NSAIDs
is considered to be primarily by inhibition of prostaglandin
synthesis (Hunashal et al., 2011). However long usage of
NSAID’s and selective cyclooxygenase-2 (COX-2) inhibitors
give unacceptable side effects such as gastric ulcer (Bush and
Imani, 1991) with NSAID’s and cardiac toxicity with coxibs.
So there is a constant need for discovery of novel and safer
anti-inﬂammatory drugs.
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biologically active compounds. Xanthene derivatives have
been reported to possess various pharmacological properties
such as antibacterial (Hideo, 1981), antiviral (Lambert et al.,
1997), anti-inﬂammatory (Poupelin et al., 1978) and CCR1
antagonist (Naya et al., 2003). Xanthenes are of great interest
in the lead optimization process of drug discovery. Some evi-
dence has surfaced that suggests the xanthene core structure
also may be useful in the design and development of pharma-
cological agents (Ornstein et al., 1998; Goodell et al., 2006).
Thus synthesis of xanthene derivatives is of immense interest.
As a result of our investigation using PASS (prediction of
activity spectra for substances) studies, it was found that 9-aryl
xanthene moiety do possess some anti-inﬂammatory activity
inﬂuenced by the substitution pattern of these molecules.
The compounds chosen for synthesis and activity determina-
tion were selected on the basis of their best prediction values
as anti-inﬂammatory and analgesic as well as ease of their
synthesis.
Reported synthetic methodologies involve harsh conditions
or longer reaction time leaving considerable scope for develop-
ment of further clean, facile and efﬁcient process for the syn-
thesis of these important molecules. The organic reactions
taking place in aqueous media have recently attracted much
attention in synthetic chemistry, not only because water is
one of the most abundant, cheapest and environmentally
friendly solvents but also because it exhibits unique reactivity
and selectivity, which is different from those observed in
conventional organic solvents (Demko and Sharpless, 2001;
Li, 2005). Apart from this, to overcome the limitations from
the catalysis point of view, we started to search for new cata-
lysts having high catalytic activity, easy availability and short
reaction time involving simple work-up procedure, and sulfa-
mic acid attracted our attention as it is known to catalyze a
number of organic transformations. Recently, sulfamic acid
has emerged as a promising solid acid catalyst for acid cata-
lyzed reactions, such as functional group protections and
deprotections and the synthesis of isoamyl acetate and poly-
meric ethers. Moreover, some important organic transforma-
tions, including the Beckmann rearrangement (Wang et al.,
2004 and Singh et al., 2004) and Bignelli condensations (Li
et al., 2003) have been performed successfully in the presence
of sulfamic acid. As a continuation of our research devoted
to the development of green route methods (Thomas et al.,
2009, 2010), herein we report an efﬁcient and convenient
method for microwave assisted synthesis of some novel
9-aryl xanthenes derivatives by condensation of aldehydes with
resorcinol in the presence of sulfamic acid as catalyst followed
by screening for in vivo anti-inﬂammatory and analgesic
activities.2. Experimental
2.1. Activity prediction
In an effort to optimize biological proﬁle, a wide structural
diversity of xanthenes possessing the 9-aryl moiety as a salient
feature of the xanthene core have been virtually designed, syn-
thesized and investigated for the foresaid pharmacological
activity. In order to accelerate search for New Chemical
Entities (NCEs), an internet version of the PASS (predictionof biological activity spectra) (http://www.ibmh.msk.su/
PASS/Ref.html) was used to predict the anti-inﬂammatory
and analgesic action of different 9-aryl xanthene derivatives.
The technique of PASS is based on the analysis of SARs for
the training set currently including about 46,000 drugs, drug
candidates and lead compounds whose biological activities
are determined experimentally. The set of MNA (multilevel
neighborhood atoms) descriptors are generated on the basis
of structural formulas presented in the MOL-ﬁle (SDF-ﬁle)
form. Since MNA descriptors are generated for each com-
pound de novo, new descriptors can be obtained upon presen-
tation of a novel structural feature in the compound under
study.
Based on the statistics of MNA descriptors for active and
inactive compounds from the training set, two probabilities
are calculated for each activity: Pa––probability of compound
being active and Pi––probability of compound is being inac-
tive. Being probabilities, the Pa and Pi values vary from
0.000 to 1.000 and in general Pa + Pi < 1, since these proba-
bilities are calculated independently.
The PASS predictions can be interpreted and used in a ﬂex-
ible manner-
(i) Only activities with Pa > Pi are considered as possible
for a particular compound.
(ii) If Pa > 0.7––the substance is very likely to exhibit activ-
ity in experiment, but chance of the substance being ana-
log of a known pharmaceutical agent is also high.
(iii) If 0.5 < Pa < 0.7––the substance is likely to exhibit the
activity in the experiment, but the probability is less and
the substance is unlike known pharmaceutical agents.
(iv) If Pa < 0.5––the substance is unlikely to exhibit the
activity in the experiment. However if the presence of
this activity is conﬁrmed in the experiment, the sub-
stance might be an NCE.
2.1.1. Selection of possible cognition enhancers
Prediction of biological activity spectra was made for about
200 virtually designed variedly substituted structures from
the theoretical calculations on the basis of PASS prediction.
The compounds screened were the structures formed from
the various combinations of R (H, 2-OH, 4-OH, 3-OCH3-4-
OH, 4-Cl and 4-NO2) groups in the hydroxylated xanthene
moiety. On the basis of prediction results from the database
analysis, potential xanthenes were selected for testing their
anti-inﬂammatory and analgesic activities. The compounds
screened above were further subjected to ‘Lipinski rules of
ﬁve’. The MIPC (mol inspiration property calculator) program
has been utilized (www.molinspiration.com) for calculating the
Lipinski descriptors. The log P values and the associated
parameters for the compounds under consideration have been
provided in Table 1 and the probabilities of the test com-
pounds for being active (Pa) are provided in Table 2. On the
basis of the above-mentioned criteria, the chosen compounds
were synthesized and experimentally tested as anti-inﬂamma-
tory and analgesic agents.
2.2. Materials and reagents
All research chemicals were purchased from Across organics
(NY, USA), Sigma–Aldrich (St. Loius, Missiouri, USA) and
Table 1 LogP values and the associated parameters for the
compounds under consideration.
Compound MLogP TPSA N atoms Mw
1a 3.985 49.69 22 290.318
1b 3.925 69.918 23 306.317
1c 3.506 69.918 23 306.317
1d 3.324 79.152 25 336.343
1e 4.663 49.69 23 324.763
1f 3.944 95.514 25 335.315
Compound nON nOHNH nViolations Nrotb
1a 3 2 0 1
1b 4 3 0 1
1c 4 3 0 1
1d 5 3 0 2
1e 3 2 0 1
1f 6 2 0 2
Table 2 The probabilities of being active Pa of the test
compounds on the basis of PASS prediction.
Compound Pa Pi
1a 0.469 0.060
1b 0.436 0.078
1c 0.467 0.061
1d 0.599 0.020
1e 0.396 0.019
1f 0.318 0.077
S482 A.G. Banerjee et al.used as such for the reactions. Melting point (m.p.) was deter-
mined by Veego melting point apparatus (VMP PM, 32/1104)
and is uncorrected. Reactions were monitored by thin layer
chromatography carried out using pre-coated silica gel plates
(E. Merck and Co., Darmstadt, Germany). Infrared (IR)
spectra (KBr) were recorded on a FTIR Spectrophotometer
(Shimadzu 8400S) with Diffuse Reﬂectance Attachment.
1H-NMR and 13C-NMR spectra were obtained using NMR
Spectrophotometer (Bruker Avance II 400 MHz NMR) with
Dimethyl Sulphoxide as solvent. Chemical shifts were
expressed in d ppm relative to tetramethylsilane (TMS) as
internal standard. A mass spectrum was obtained on a Hewlett
Packard model GCD-1800A Electron Impact mass spectrom-
eter at 70 eV ionizing beam and using direct insertion probe.
Elemental analyses of the new compounds (C, H and N) were
performed with a Perkin Elmer 2400-CHN Elemental Ana-
lyzer instrument and the results were within ±0.4% of the the-
oretical values.
2.3. Synthesis
2.3.1. Synthesis of 9-aryl-9H-xanthene-3,6-diol derivatives
Resorcinol (2 mM) was reacted with various aromatic
aldehydes (1 mM) and sulfamic acid (0.04 mM) as a catalyst
in required quantity of water in a two necked round bottom
ﬂask (RBF). The mixtures were irradiated in a microwave at-
tached with reﬂux condenser and constant stirring to avoid
risk of high pressure development (Make-Raga’s Scientiﬁc)
at 350 W (110 C) till the completion of the reaction. The reac-tion was monitored by TLC (n-Hexane:Ethyl Acetate 1:1).
After completion of the reaction, the reaction mixture was
cooled to room temperature and ice was added along with stir-
ring. The mixture was extracted with ethyl acetate two to three
times in a separating funnel and the organic layer was evapo-
rated to dryness. The crude products on recrystallisation from
hot ethanol gave the pure 9-aryl xanthene derivatives (1a–f).
The synthesized compounds were characterized by their melt-
ing point and spectral data (IR, 1H-NMR). Tables 3 and 4
represents structure, properties and spectral data of synthe-
sized 9-aryl xanthenes derivatives.
2.3.1.1. 9-Phenyl-9H-xanthene-3,6-diol (1a). Buff colored
powder; Yield 77.34%; m.p. 172–175 C. IR (KBr):
m/cm1 = 3475–3224 (OH), 3091–3029 (CH), 1610, 1514,
1429 (ring C‚C), 1076 (ether C–O); 840, 748, 702 (CH).
1H-NMR (DMSO-d6): d ppm = 5.15 (b.s, 2H, -OH), 5.76 (s,
1H, CH), 6.21–7.10 (m, 11H, Ar-H), 6.32 (s, 1H), 6.90 (d,
2H), 7.08 (s, 1H), 7.10 (s, 2H). EIMS (70 eV, m/z) 290
(M+). MW: 290.31 Anal. Calcd for C19H14O3: C, 78.61; H,
4.86. Found: C, 78.34; H, 4.98.
2.3.1.2. 9-(2-Hydroxyphenyl)-9H-xanthene-3,6-diol (1b).
Yellow powder; Yield 78.52%; m.p. 132–134 C. IR (KBr):
m/cm1 = 3463–3205 (OH), 3151–3037 (CH), 1606, 1508,
1454 (ring C‚C), 1076 (ether C–O); 837, 756 (CH).
1H-NMR (DMSO-d6): d ppm= 5.43 (s, 3H, -OH), 5.63 (s,
1H, CH), 6.21–6.86 (m, 10H, Ar-H), 6.27 (s, 2H), 6.49 (d,
2H), 6.86 (d, 2H). EIMS (70 eV, m/z) 306 (M+). MW:
306.31 Anal. Calcd for C19H14O4: C, 74.50; H, 4.61. Found:
C, 74.69; H, 4.68.
2.3.1.3. 9-(4-Hydroxyphenyl)-9H-xanthene-3,6-diol (1c).
Yellow powder; Yield 80.62%; m.p. 129–131 C. IR (KBr):
m/cm1 = 3292–3178 (OH), 3129–3076 (CH); 1604, 1510,
1431(ring C‚C), 1076 (ether C–O), 844, 577 (CH).
1H-NMR (DMSO-d6): d ppm= 5.48 (s, 1H, -OH), 5.69 (s,
2H, -OH), 5.77 (s, 1H, CH), 6.13–6.82 (m, 6H, Ar-H), 6.37 (s,
2H), 6.53 (d, 2H), 6.63 (d, 2H), 6.82 (d, 2H). EIMS (70 eV, m/
z) 306 (M+). MW: 306.31 Anal. Calcd for C19H14O4: C, 74.50;
H, 4.61. Found: C, 74.76; H, 4.54.
2.3.1.4. 9-(4-Hydroxy-3-methoxyphenyl)-9H-xanthene-3,6-diol
(1d). Orange crystals; Yield 76.54%; m.p. 199–202 C. IR
(KBr): m/cm1 = 3259–3190 (OH), 3156–3028 (CH); 1604,
1512, 1427 (ring C‚C), 1076 (ether C–O), 844, 767 (CH).
1H-NMR (DMSO-d6): d ppm= 3.59 (s, 3H, OCH3), 5.23 (s,
2H, -OH), 5.48 (s, 1H, -OH), 5.73 (s, 1H, CH), 6.15–6.98 (m,
9H, Ar-H), 6.35 (s, 2H), 6.37 (s, 2H), 6.94 (d, 2H). EIMS
(70 eV, m/z) 336 (M+). MW: 336.34 Anal. Calcd for
C20H16O5: C, 71.42; H, 4.79. Found: C, 71.56; H, 4.68.
2.3.1.5. 9-(4-Chlorophenyl)-9H-xanthene-3,6-diol (1e). Yellow
crystals; Yield 82.00%; m.p. > 225 C. IR (KBr): m/cm1 =
3510–3328 (OH), 3192–3045 (CH); 1612, 1496, 1431 (ring
C‚C), 1087 (ether C–O), 844, 767 (CH); 725 (C-l).
1H-NMR (DMSO-d6): d ppm= 5.28 (s, 2H), 5.45 (s, 1H),
6.21–6.68 (m, 6H, Ar-H), 6.24 (s,2H), 6.67,6.68 (d,2H), 6.90,
6.93 (d, 2H), 7.18,7.21 (d, 2H). EIMS (70 eV, m/z) 324
(M+), 326 (M+ 2H). MW: 324.76 Anal. Calcd for
C19H13ClO3: C, 70.27; H, 4.03. Found: C, 70.02; H, 3.88.
Table 3 Chemical structures and properties of 9-aryl xanthenes (1a–f).
Compounds Ar Yield (%)
(Reaction
time)
Rf valuea Melting
point (C)b
(Recrys. solvent)
Solubility Molecular
formula
(Molecular
weight)
Analysis (%) Calcd/Found M+ 70 eV EI
C H N
1a 77.34
(10 min)
0.33 172–175
(Ethanol)
Ethanol C19H14O3
(290.31)
78.61
78.34
4.86
4.98
– 290
1b 78.52
(10 min)
0.37 132–134
(Ethanol)
Ethanol C19H14O4
(306.31)
74.50
74.69
4.61
4.68
– 306
1c 80.62
(10 min)
0.38 129–131
(Ethanol)
Ethanol C19H14O4
(306.31)
74.50
74.76
4.61
4.54
– 306
1d 76.54
(10 min)
0.40 199–202
(Ethanol)
Ethanol C20H16O5
(336.34)
71.42
71.56
4.79
4.68
– 336
1e 82.00
(8 min)
0.42 >225
(Ethanol)
Ethanol C19H13ClO3
(324.76)
70.27
70.02
4.03
3.88
– 326
1f 82.74
(8 min)
0.46 >225
(Ethanol)
Ethanol C19H13NO5
(335.31)
68.06
68.32
3.91
4.14
4.18 4.16 335
a Stationary phase: silica gel G, mobile phase: n-hexane:ethyl acetate (1:1), iodine vapors as visualizing agent.
b All melting points were uncorrected.
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crystals; Yield 82.74%; m.p. > 225 C. IR (KBr): m/cm1 =
3321–3228 (OH), 3116–3078 (CH); 1604, 1512, 1431 (ring
C‚C), 1345 (symmetric NO), 1091 (ether C-7 O), 844 (Sym-metric NO), 744, 702, 628 (CH). 1H-NMR (DMSO-d6): d
ppm= 5.38 (s, 2H), 5.63 (s, 1H), 6.30–6.73 (m, 6H, Ar-H),
6.30 (s, 2H), 6.83,6.88 (d, 2H), 7.30, 7.33 (d,2H), 8.18, 8.21
(d,2H). 13C-NMR (DMSO-d6, 62.9 MHz) d 173.5, 155.3,
Table 4 1H-NMR spectral data of the synthesized compounds.
Compound No. 1H-NMR d (ppm)
1a 5.15 (b.s, 2H, -OH), 5.76 (s, 1H, CH), 6.21–7.10 (m, 11H, Ar-H), 6.32 (s,1H), 6.90 (d, 2H), 7.08 (s, 1H)
1b 5.43 (s, 3H, -OH), 5.63 (s, 1H, CH), 6.21–6.86 (m, 10H, Ar-H), 6.27 (s, 2H), 6.49 (d, 2H), 6.86 (d,2H)
1c 5.48 (s, 1H, -OH), 5.69 (s, 2H, -OH), 5.77 (s, 1H, CH), 6.13–6.82 (m, 6H, Ar-H), 6.37 (s, 2H), 6.53 (d, 2H), 6.63 (d, 2H),
6.82 (d, 2H)
1d 3.59 (s, 3H, OCH3), 5.23 (s, 2H, -OH), 5.48 (s, 1H, -OH), 5.73 (s, 1H, CH), 6.15–6.98 (m, 9H, Ar-H), 6.35 (s, 2H), 6.37 (s,
2H), 6.94 (d, 2H)
1e 5.28 (s, 2H), 5.45 (s, 1H), 6.21–6.68 (m, 6H, Ar-H), 6.24 (s,2H), 6.67,6.68 (d,2H), 6.90, 6.93 (d, 2H), 7.18,7.21 (d, 2H)
1f 5.38 (s, 2H), 5.63 (s, 1H), 6.30–6.73 (m, 6H, Ar-H), 6.30 (s, 2H), 6.83,6.88 (d, 2H), 7.30, 7.33(d,2H), 8.18,8.21(d,2H)
S484 A.G. Banerjee et al.147.0, 146.1, 139.7, 131.0, 130.1, 122.4, 121.1, 113.5, 103.6
EIMS (70 eV, m/z) 335 (M+). MW: 335.31 Anal. Calcd for
C19H13NO5: C, 68.06; H, 3.91; N, 4.18. Found: C, 68.32; H,
4.14; N, 4.00.
2.4. Pharmacology
2.4.1. Experimental animals
Wistar rats (150–220 g) and Swiss albino mice (20–25 g) of
either sex were obtained from National Toxicological Centre
(NTC) Pune and Serum India Ltd. Pune (India) respectively
for the experimental studies. The animals were housed in poly-
propylene cages at a room temperature (25 ± 2 C) with 12 h
of light and dark cycles and had free access to standard pellet
diet and water ad libitum. On the day before the treatments,
food was withdrawn, but the animals were allowed free access
of water. The allocation of animals to different groups was
randomized and the experiments were carried out under blind
conditions. Animals used in the present study were cared for as
per guidelines of the Committee for the purpose of control and
supervision on experiments on animals (CPCSEA), Dept. of
Animal Welfare, Govt. of India procedures involving animals
and their care were conducted in conformity with international
laws and policies and animal studies accepted by the Institu-
tional Animal Ethics Committee (IAEC Reg. No. DYPIPSR/
IEAC/08-09/P-26).
2.4.2. Acute toxicity determination
The acute toxicity study for the test drugs was carried out in
mice according to the OECD guidelines (OECD-423, 2004).
Albino mice of either sex weighing between 20 and 25 g were
divided into six groups of six animals each. Animals were
starved for 24 h with water ad libitum prior to test. On the
day of the experiment, test drugs were administered at graded
doses up to 2000 mg/kg, p.o. and animals were monitored indi-
vidually and continuously for 30 min, 2 h and up to 24 h to de-
tect any changes in the autonomic or behavioral responses and
also for tremors, convulsions, excessive salivation, diarrhea,
lethargy, sleep and coma. The animals were then monitored
for any mortality for the following 14 days. As there was no
toxic reaction or mortality observed, the test drugs were found
to be devoid of any toxicity up to a maximum dose of
2000 mg/kg body weight.
2.4.3. Anti-inﬂammatory activity
In vivo anti-inﬂammatory activity was evaluated by carra-
geenan induced rat paw edema assay model (Winter et al.,
1962). Rats were divided into different groups each consisting
of 8 animals and administered with 0.5% sodium CMC(10 ml/kg p.o.) as control group, reference standard indometh-
acin (10 mg/kg p.o.) and test compounds 1a–f were adminis-
tered at the dose of 30, 60 and 90 mg/kg p.o. One hour after
dosing, the rats were challenged by a sub plantar injection of
0.05 ml of 1% solution of carrageenan (Sigma, St. Louis,
Missouri, USA) in sterile distilled water which was adminis-
tered to the left hind footpad of each animal. The total increase
in edema volume is measured by mercury displacement tech-
nique with the help of the plethysmometer (UGO Basile, Italy)
at 1, 2, 3, 4, 5 and 6 h after carrageenan treatment. The per-
centages of the inhibition in the treated animals versus control
group were calculated at each 60 min interval by using the fol-
lowing formula:
%Inhibition ¼ Ec Et=Ec 100 ð1Þ
Ec =Mean of edema volume of control group.
Et =Mean of edema volume of test group.
2.4.4. Gastric ulcerogenicity
Animals were subjected to acute ulcerogenic effect after
administration of control group 0.5% sodium CMC
(10 ml/kg p.o.), test drugs (30, 60 and 90 mg/kg p.o.) and stan-
dard Indomethacin (10 mg/kg p.o.). Twenty four hours after
the dosing, rats under deep ether anesthesia were sacriﬁced
so that the stomach could be removed, opened along the
curvature and cleaned gently by dipping in saline. Then the
stomachs were examined for lesions under a dissecting micro-
scope. Stomachs exhibiting one or more ulcers were considered
positive (Hafez et al., 2010).2.4.5. Analgesic activity
2.4.5.1. Acetic acid induced writhing in mice (Koster et al.,
1959). The mice were fasted overnight and provided water ad
libitum and divided into different groups each consisting of
eight animals. Mice were administered with 0.5% sodium
CMC (control, 10 ml/kg, p.o.), Aspirin (300 mg/kg, p.o.) and
Indomethacin (10 mg/kg p.o.) as reference standards and test
compounds (1a–f) at the dose of 150 and 300 mg/kg. The
number of writhing episodes was counted for 30 min following
acetic acid injection (0.6% v/v). A signiﬁcant reduction in the
number of writhings by any treatment as compared to the
number of writhings in control animals was considered a posi-
tive analgesic response. The analgesic activity was expressed as
a percentage change from writhing controls.
2.4.5.2. Formalin-induced paw edema bioassay. The anti-
nociceptive effect was also evaluated by this sub-acute
inﬂammatory model. The mice were fasted overnight and pro-
A facile microwave assisted one pot synthesis of novel xanthene derivatives S485vided water ad libitum and divided into different groups each
consisting of 5 animals. After administration of the test drugs
and subplantar route of formalin 0.02 ml (1%), the time (sec-
onds) which each mice spent licking was observed. Mice were
administered with 0.5% sodium CMC (10 ml/kg p.o.) as con-
trol group, pentazocin (10 mg/kg i.p.) and Indomethacin
(10 mg/kg p.o.) as reference standards and test compounds
(1a–f) at the dose of 150 mg/kg p.o. and 300 mg/kg p.o. The
amount of time spent licking the injected paw was timed,
and was considered as indicative of pain. The ﬁrst of the noci-
ceptive response normally peaked 5 min after formalin injec-
tion and the second phase 15–30 min after formalin
injection, representing the neurogenic and inﬂammatory pain
responses, respectively (Hunskaar and Hole, 1987). The ani-
mals were pretreated with samples 1 h before being challenged
with buffered formalin, and the responses were observed for
30 min.
2.4.6. Statistical analysis
All values in the texts are expressed as means ± standard error
of the mean (SEM) for n observations, where n represents
number of animals studied. The results were analyzed by one
way analysis of variance (ANOVA) followed by Dunnett’s
test. ‘p’ values more than 0.05 was considered as non signiﬁ-
cant, less than 0.05 as signiﬁcant and less than 0.01 as extre-
mely signiﬁcant compared with control group.Scheme 1 Synthesis of 9-aryl xanthen
Scheme 2 Reacti3. Results and discussion
3.1. Chemistry
The use of sulfamic acid as a catalyst to bring about the con-
densation of resorcinol with different aryl aldehydes afforded
the ﬁnal products (1a–f) in good yields. The best results were
obtained using 0.04 mmol of the catalyst. Using lower
amounts of the catalyst resulted in lower yields, while higher
amounts of the catalyst did not affect the reaction rate and
yields. However in the absence of catalyst, the yield of the
product was found to be very low wherein starting materials
remained intact along with some undesired impurities. An-
other advantage of using sulfamic acid as a catalyst is in its
ability to provide conditions which are mild enough not to
damage moieties such as methoxy substituent which often
undergoes cleavage in strongly acidic reaction conditions.
The synthetic route for the synthesis of compounds (1a–f)
with plausible mechanism is outlined in Schemes 1 and 2.
Based on the synthetic method for ﬂuorescein synthesis, resor-
cinol which undergoes electrophilic reactions same as phenol
was selected for the xanthene synthesis. The presence of two
hydroxyl groups present in resorcinol strongly activates the
ortho and para positions of the benzene ring. The ortho–ortho
position with respect to each hydroxyl group is sterically
hindered for bulkier substitution and hence the possiblee derivatives by microwave method.
on mechanism.
Table 5 Carrageenan-induced paw edema and incidence of gastric ulcers in rats.
Compound
(n= 8)
Dose
(mg/kg p.o.)
Dose (mg/kg p.o.) % Animals with
ulcersEdema volume (ml) mean ± SEM (% inhibition)
60 min 120 min 180 min 240 min 300 min 360 min
Control 10 0.45 ± 0.027 0.57 ± 0.033 0.64 ± 0.046 0.76 ± 0.045 0.93 ± 0.062 0.87 ± 0.052 –
Indo 10 0.15 ± 0.009** (66.67) 0.14 ± 0.008** (75.43) 0.12 ± 0.008** (81.25) 0.098 ± 0.006** (87.11) 0.091 ± 0.004** (90.22) 0.09 ± 0.005** (89.66) 7/8 (87.5)
1a 30 0.44 ± 0.035 (2.22) 0.54 ± 0.040 (5.26) 0.59 ± 0.035 (7.81) 0.66 ± 0.049 (13.15) 0.70 ± 0.059* (24.73) 0.63 ± 0.028* (27.58) 0/8 (0)
60 0.43 ± 0.035 (4.44) 0.52 ± 0.041 (8.77) 0.55 ± 0.034 (14.06) 0.64 ± 0.042 (15.78) 0.63 ± 0.055* (32.25) 0.57.±0.029** (34.48) 0/8 (0)
90 0.42 ± 0.037 (6.66) 0.49 ± 0.039 (14.03) 0.49 ± 0.036* (23.43) 0.57 ± 0.033* (25.0) 0.55 ± 0.049** (40.86) 0.50 ± 0.024** (42.52) 1/8 (12.5)
1b 30 0.43 ± 0.029 (4.44) 0.53 ± 0.038 (7.01) 0.57 ± 0.030 (10.93) 0.64 ± 0.045 (15.78) 0.62 ± 0.049* (33.33) 0.57 ± 0.029** (34.48) 0/8 (0)
60 0.42 ± 0.031 (6.66) 0.52 ± 0.039 (8.77) 0.54 ± 0.035 (15.62) 0.60 ± 0.042* (21.05) 0.55 ± 0.042** (40.86) 0.51.±0.027** (41.37) 0/8 (0)
90 0.41 ± 0.033 (8.88) 0.48 ± 0.038 (15.79) 0.51 ± 0.035* (20.31) 0.56 ± 0.040* (26.31) 0.49 ± 0.031** (47.31) 0.47 ± 0.022** (45.97) 0/8 (0)
1c 30 0.42 ± 0.035 (6.66) 0.52 ± 0.039 (8.77) 0.55 ± 0.035 (14.06) 0.60 ± 0.031* (21.05) 0.50 ± 0.020** (46.23) 0.48 ± 0.024** (44.82) 0/8 (0)
60 0.41 ± 0.028 (8.88) 0.50 ± 0.032 (12.28) 0.51 ± 0.022 (20.31) 0.56 ± 0.019* (26.31) 0.45 ± 0.029** (51.61) 0.44.±0.018** (49.42) 0/8 (0)
90 0.40 ± 0.028 (11.11) 0.49 ± 0.035 (14.03) 0.50 ± 0.018* (21.87) 0.51 ± 0.022* (32.39) 0.42 ± 0.016** (54.83) 0.41 ± 0.019** (52.87) 0/8 (0)
1d 30 0.40 ± 0.030 (11.11) 0.50 ± 0.039 (12.28) 0.53 ± 0.035 (17.18) 0.58 ± 0.048* (23.68) 0.48 ± 0.031** (48.38) 0.46 ± 0.029** (47.12) 1/8 (12.5)
60 0.39 ± 0.031 (13.33) 0.48 ± 0.039 (15.78) 0.48 ± 0.026* (25.0) 0.51 ± 0.038* (32.89) 0.42 ± 0.022** (54.83) 0.41.±0.021** (52.87) 1/8 (12.5)
90 0.38 ± 0.025 (15.55) 0.47 ± 0.038 (17.54) 0.46 ± 0.025* (28.12) 0.46 ± 0.029** (39.47) 0.38 ± 0.022** (59.13) 0.36 ± 0.020** (58.62) 2/8 (25)
1e 30 0.42 ± 0.029 (6.66) 0.48 ± 0.039 (15.78) 0.48 ± 0.024* (25.0) 0.43 ± 0.039** (43.42) 0.39 ± 0.028** (58.06) 0.37 ± 0.020** (57.47) 2/8 (25)
60 0.39 ± 0.028 (13.33) 0.46 ± 0.032 (19.29) 0.41 ± 0.022** (35.93) 0.36 ± 0.029** (52.63) 0.34 ± 0.016** (63.44) 0.33 ± 0.019** (62.06) 4/8 (50)
90 0.40 ± 0.025 (11.11) 0.44 ± 0.034* (22.80) 0.36 ± 0.027** (43.75) 0.33 ± 0.022** (56.57) 0.30 ± 0.016** (67.74) 0.29 ± 0.019** (66.66) 4/8 (50)
1f 30 0.41 ± 0.032 (9.75) 0.49 ± 0.035 (14.03) 0.50 ± 0.034* (21.87) 0.54 ± 0.045** (28.94) 0.42 ± 0.020** (54.83) 0.38 ± 0.031** (56.32) 1/8 (12.5)
60 0.40 ± 0.035 (11.11) 0.46 ± 0.041 (19.29) 0.46 ± 0.031* (28.12) 0.48 ± 0.029** (36.84) 0.36 ± 0.016** (61.29) 0.34.±0.019** (60.91) 1/8 (12.5)
90 0.37 ± 0.034 (17.77) 0.45 ± 0.039* (21.05) 0.43 ± 0.027* (32.81) 0.42 ± 0.029** (44.73) 0.32 ± 0.021** (65.59) 0.30 ± 0.018** (65.51) 2/8 (25)
Each value is the mean ± SEM of eight rats. Statistical analysis by one way ANOVA followed by Dunnett’s test.
Control: 0.5% sodium CMC solution in distilled water (10 ml/kg p.o.).
Indo: Reference standard Indomethacin (10 mg/kg p.o.).
1a: 9-Phenyl-9H-xanthene-3,6-diol.
1b: 9-(2-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1c: 9-(4-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1d: 9-(4-Hydroxy-3-methoxyphenyl)-9H-xanthene-3,6-diol.
1e: 9-(4-Chlorophenyl)-9H-xanthene-3,6-diol.
1f: 9-(4-Nitrophenyl)-9H-xanthene-3,6-diol.
* p< 0.05, compared with control.
** p< 0.01, compared with control.
S
4
8
6
A
.G
.
B
a
n
erjee
et
a
l.
A facile microwave assisted one pot synthesis of novel xanthene derivatives S487substitution is at the para position. The condensation of resor-
cinol with different substituted aldehydes gave 75–85% yield
irrespective of the reactivity factors involved with benzalde-
hyde substituted with electron donating groups like the hydro-
xy group and the electron withdrawing groups like the nitro,
chloro substituted aldehydes. Apart from this, the presenceTable 6 Acetic acid writhing and formalin tests of 9-aryl xanthene
Compound (n= 5) Dose (mg/kg p.o.) Total no. of writ
(Mean ± SEM)
(% inhibition)
Control 10 40.0 ± 2.19
Indomethacin 10 9.40 ± 0.60**(76
Pentazocin 10 (i.p.) –
Aspirin 300 15.40 ± 1.30** (6
1a 150 16.8 ± 1.40** (5
1b 150 35.2 ± 3.16(12.0
1c 150 32.8 ± 1.85(18.0
1d 150 17.8 ± 1.49** (5
1e 150 14.2 ± 1.38** (6
1f 150 30.2 ± 2.67*(24.
Each value is the mean ± SEM of ﬁve mice. Statistical analysis by one w
Control: 0.5% sodium CMC solution in distilled water (10 ml/kg p.o.).
1a: 9-Phenyl-9H-xanthene-3,6-diol.
1b: 9-(2-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1c: 9-(4-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1d: 9-(4-Hydroxy-3-methoxyphenyl)-9H-xanthene-3,6-diol.
1e: 9-(4-Chlorophenyl)-9H-xanthene-3,6-diol.
1f: 9-(4-Nitrophenyl)-9H-xanthene-3,6-diol.
* p< 0.05, compared with control.
** p< 0.01, compared with control.
Table 7 Acetic acid writhing and formalin tests of 9-aryl xanthene
Compound (n= 5) Dose
(mg/kg p.o.)
Total no. of writhin
(Mean ± SEM)
(% inhibition)
Control 10 41.4 ± 1.80
INDO 10 9.8 ± 0.73** (76.32
Pentazocin 10 (i.p.) –
Aspirin 300 14.4 ± 1.26** (65.21
1a 300 15.0 ± 1.14** (63.76
1b 300 34.6 ± 2.69(16.42)
1c 300 32.4 ± 2.12* (21.73)
1d 300 16.6 ± 1.56** (59.90
1e 300 13.6 ± 1.12** (67.14
1f 300 29.8 ± 2.67* (28.01)
Each value is the mean ± SEM of ﬁve mice. Statistical analysis by one w
Control: 0.5% sodium CMC solution in distilled water (10 ml/kg p.o.).
1a: 9-Phenyl-9H-xanthene-3,6-diol.
1b: 9-(2-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1c: 9-(4-Hydroxyphenyl)-9H-xanthene-3,6-diol.
1d: 9-(4-Hydroxy-3-methoxyphenyl)-9H-xanthene-3,6-diol.
1e: 9-(4-Chlorophenyl)-9H-xanthene-3,6-diol.
1f: 9-(4-Nitrophenyl)-9H-xanthene-3,6-diol.
* p< 0.05 compared with control,
** p< 0.01.of water was found in this case to strongly enhance the reac-
tion rates which may be attributed to the presence of a polar
group compound in the reaction enabling some degree of sol-
ubility in water.
The series of 9-aryl-9H-xanthene-3,6-diol derivatives with
the xanthenes nucleus synthesized by the microwave methodderivatives (150 mg/kg) in mice.
hings Time spent with licking (sec)
(Mean ± SEM)
(% inhibition)
Phase I (0–10 min) Phase II (15–30 min)
161.2 ± 2.42 131.0 ± 3.05
.5) 121.66 ± 4.41** (24.53) 70.33 ± 3.83** (46.67)
82.67 ± 4.10** (48.72) 54.33 ± 2.96** (58.53)
1.5) – –
8.0) 152.2 ± 1.98 * (5.58) 94.80 ± 3.29** (27.63)
) 156.8 ± 1.68(2.72) 118.8 ± 2.33(9.31)
) 151.0 ± 1.66 * (5.95) 118.4 ± 5.68(9.61)
5.5) 151.2 ± 1.56 * (6.20) 103.6 ± 1.72** (20.91)
4.5) 150.8 ± 2.37 * (6.45) 90.40 ± 2.71 ** (31.0)
5) 154.6 ± 1.77(4.09) 117.4 ± 3.95* (10.38)
ay ANOVA followed by Dunnett’s test.
derivatives (300 mg/kg) in mice.
gs Time spent with licking (sec)
(Mean ± SEM)
(% inhibition)
Phase I(0–10 min) Phase II(15–30 min)
164.60 ± 2.06 132.2 ± 2.51
) 123.0 ± 1.15** (25.27) 71.0 ± 3.05** (46.29)
85.0 ± 2.30** (48.35) 56.33 ± 2.33** (57.39)
) – –
) 152.8 ± 5.41* (7.16) 93.4 ± 2.78** (29.34)
159.4 ± 1.86(3.16) 123.2 ± 2.87(6.80)
154.8 ± 2.26(5.95) 121.8 ± 2.26(7.86)
) 151.8 ± 1.77* (7.77) 99.2 ± 2.45** (24.96)
) 151.4 ± 2.69* (8.01) 88.4 ± 2.54** (33.13)
154.0 ± 2.34(5.22) 116.2 ± 4.29* (12.10)
ay ANOVA followed by Dunnett’s test.
S488 A.G. Banerjee et al.was characterized by the presence of strong band at 1072–
1091 cm1 for the ether linkage formed, considered to be a
strong conﬁrmation for formation of xanthene nucleus. An-
other piece of evidence for cyclization is the appearance of sin-
glet signal equivalent to 1 proton in the 1H-NMR spectrum
between 5.9 and 6.1 ppm (C-9, CH) which represents the for-
mation of the xanthenes nucleus. The mass spectra and ele-
mental analysis further conﬁrmed the assigned structures.
The physical and spectroscopic data of the synthesized com-
pounds are given in Tables 3 and 4.
3.2. Pharmacology
All the newly synthesized 9-aryl xanthene derivatives were
tested for in vivo anti-inﬂammatory, analgesic, and ulcerogenic
activities.
3.2.1. Anti-inﬂammatory activity
Carrageenan induced paw edema model is used to study and
evaluate the effects of acute inﬂammation involving various
types of inﬂammatory mediators like histamine, serotonin,
bradykinin and prostaglandin (Vinger et al., 1987). The anti-
inﬂammatory activity of synthesized derivatives (1a–f) were as-
sessed from their ability to inhibit the paw edema induced by
carrageenan in mice and activity was expressed as ‘‘mean in-
crease in paw volume ± SEM’’, in terms of millimeters (mm)
and percentage inhibition in paw volume by different doses
of the compounds. As observed from the results in Table 5,
the compounds (1a–f) possessed signiﬁcant anti-inﬂammatory
activity at second phase (at a time interval between 180 and
360 min) at a dose of 30, 60 and 90 mg/kg dose p.o.
Edema produced by carrageenan is a biphasic event in
which the involvement of the cyclooxygenase products of ara-
chidonic acid metabolism and the production of reactive oxy-
gen species are well established. (Smith et al., 1974). If the
inhibition is more effective in the ﬁrst phase of carrageenan-
induced edema, it indicates that the anti-inﬂammatory effect
is taking place through the inhibition of the pathway mediated
by is histamine and serotonin. In addition, if the inhibition is
more effective in the second phase of carrageenan-induced ede-
ma, it indicates that the anti-inﬂammatory effect is taking
place through the inhibition of the pathway mediated by pros-
taglandin (PG) (Holsapple et al., 1980). According to this liter-
ature information, it might be stated that the synthesized
xanthene derivatives (1a–f) exhibit their anti-inﬂammatory ef-
fect through the PG mediated mechanism (Table 5).
3.2.2. Ulcerogenic activity
In order to determine the extent of these side effects, the com-
pounds were further tested for ulcerogenicity. The ulcerogenic
liabilities of compounds (1a–f) were either absent or less than
that of indomethacin at all three graded doses. The results
indicating% inhibition of inﬂammation and% of animals
found ulcerogenic has been shown in Table 5.
3.2.3. Analgesic activity
3.2.3.1. Acetic acid-induced writhing test (Gonzalez et al.,
2001). Acetic acid induces pain by increasing ﬂuids of PGE2
and PGF2a (Deraedt et al., 1980) at the peritoneal receptors.
It has been postulated that acetic acid acts indirectly by
inducing the release of endogenous mediators, which in turn
stimulates the nociceptive neurons that are sensitive to non-steroidal anti-inﬂammatory drugs and narcotics (Bentley
et al., 1983; Collier et al., 1968). In the acetic acid induced writh-
ing test the analgesic activity of the compounds are expressed as
‘‘mean increase in latency after drug administration ± SEM’’
relative to control and percentage inhibition in writhing reﬂex.
Although the derivatives 1b, 1c showed some activity, it is not
signiﬁcant statistically. Among the remaining, the derivatives
1f, 1a, 1d and 1e exhibited signiﬁcant activity. In the acetic
acid-induced writhing test, derivative 1e exhibited higher anal-
gesic activity than aspirin with percentage inhibition values
64.50%, 67.14%, respectively, at 100 and 150 mg/kg dose level.
3.2.3.2. Formalin induced model. In the formalin test, pretreat-
ment of mice with the 9-aryl xanthene derivatives (1a–f) at the
doses of 150 and 300 mg/kg had signiﬁcant effect during the ﬁrst
phase of the test (0–5 min) and the second phase (15–30 min)
(Tables 6 and 7) except derivative 1b which was not having sig-
niﬁcant activity at both the phases. The formalin test assesses
the behavioral response to injection of dilute formation into
the paw of an animal. The formalin-induced pain test deﬁnes
two distinct periods of response, i.e. early response (tonic pain
response) and late phase (inﬂammatory pain response). The re-
sponse consists of licking and elevation (lifting) of the injected
paw, ﬂinching, and also protection of the paw from full pressure
when walking or resting (Porro and Cavazzuti, 1993). Drugs
that act primarily on the CNS inhibit both phases equally while
peripherally acting drugs inhibit the late phase (Tjolsen et al.,
1992). The ability of 9-aryl xanthenes derivatives to have an ef-
fect on the second phase indicates that the 9-aryl xanthenes con-
tain an active analgesic principle acting peripherally and not
through CNS as shown by indomethacin and pentazocin.
4. Conclusion
 In summary, 9-aryl-9H-xanthene-3,6-diol derivatives were
synthesized by microwave assisted synthesis using sulfamic
acid as a catalyst and water as a solvent with satisfactory
yields. Compared to other conventional methods, the
reported route of synthesis provided several advantages
such as mild reaction conditions, shorter reaction times thus
supporting to the cause of Green Chemistry.
 On the basis of anti-inﬂammatory and analgesic studies it
was observed that test compounds 1e and 1f showed com-
parable activity as compared to standard drugs.
 Results also showed that the synthesized 9-aryl xanthenes
derivatives are less ulcerogenic as compared to standard
drug indomethacin.
 In conclusion, the ﬁndings of the above study are necessary
as they shed light onto a series of novel 9-aryl xanthenes as
lead compounds having anti-inﬂammatory and analgesic
effects which can be further exploited in the search of
New Chemical Entities (NCE’s).Acknowledgments
The authors are thankful to the University of Pune, Pune
(India) for providing ﬁnancial support and Padm. Dr. D.Y.
Patil Institute of Pharmaceutical Sciences and Research, Pune
(India) for providing necessary facilities to carry out this work.
Authors are also grateful to SAIF/CIL, Panjab University,
Chandigarh (India) for providing spectral data.
A facile microwave assisted one pot synthesis of novel xanthene derivatives S489References
Bentley, G.A., Newton, S.H., Starr, J., 1983. British J. Pharmacol. 79,
125–134.
Bush, T.M., Imani, K., 1991. West. J. Med. 155, 39–42.
Collier, H.O.J., Dinneen, L.C., Johnson, C.A., Schneider, C., 1968.
British J. Pharmacol. 32, 295–310.
Demko, Z.P., Sharpless, K.B., 2001. J. Org. Chem. 66, 7945–7950.
Deraedt, R., Jougney, S., Delevalcee, F., Falhout, M., 1980. Eur. J.
Pharmacol. 51, 17–24.
Gonzalez, F.G., Portela, T.Y., Stipp, E.J., Di Stasi, L.C., 2001. J.
Ethnopharmacol. 77, 41–47.
Goodell, J.R., Puig-Basagoiti, F., Forshey, B.M., Shi, P.Y., Ferguson,
D.M., 2006. J. Med. Chem. 49, 2127–2137.
Hafez, H.N., Abdel Rahman, B.A., El-Gazzar, Galal, A.M.N., 2010.
Eur. J. Med. Chem. 45, 1485–1493.
Hideo, T., Jpn. Tokkyo koho, 1981. Chem. Abstr. 95, (80922b, JP
56005480).
Holsapple, M.P., Schuner, M., Yim, G.K.W., 1980. Agents Actions 10,
368–373.
Hunashal, R.D., Ronad, P.M., Maddi, V.S., Satyanarana, D.,
Kamadod, M.A. 2011. Arabian J. Chem. (10.1016/
j.arabjc.2011.01.003)
Hunskaar, S., Hole, K., 1987. Pain 30, 103–113.
Koster, R., Anderson, R., De Beer, E.J., 1959. Acetic acid for analgesic
screening. Federation Proceedings 18, 412–416.
Lambert, R.W., Martin, J.A., Merrett, J.H., Parker, K.E.B., Thomas,
G.J., PCT Int. Appl. 1997. Chem. Abstr. 126 (212377y, WO
9706178).
Li, C.J., 2005. Chem. Rev. 105, 3095–3166.Li, J.T., Han, J.F., Yang, J.H., Li, T.S., 2003. Ultrason. Sonochem. 10,
119–122.
Naya, A., Ishikawa, M., Matsuda, K., Ohwaki, K., Saeki, T., Naguchi,
K., Ohtake, N., 2003. Bioorg. Med. Chem. 11, 875–884.
Ornstein, P.L., Arnold, M.B., Bleisch, T.J., Wright, R.A., Wheeler,
W.J., Schoepp, D.D., 1998. Bioorg. Med. Chem. Lett. 8, 1919–
1922.
Porro, C.A., Cavazzuti, M., 1993. Progress in Neurobiology 41, 565–
607.
Poupelin, J.P., Ruf, G.S., Blanpin, O.F., Narcisse, G., Ernouf, G.U.,
Lacroix, R., 1978. Eur. J. Med. Chem. 13, 67–71.
Singh, P.R., Singh, D.U., Samant, S.D., 2004. Synlett, 1909–1912.
Smith, M.J.H., Ford-Hutchinson, A.W., Elliot, P.N.C., Bolam, J.,
1974. J. Pharm. Pharmacol. 26, 692–698.
Thomas, A.B., Tupe, P.N., Badhe, R.V., Nanda, R.K., Kothapalli,
L.P., Paradkar, O.D., Sharma, P.A., Deshpande, A.D., 2009.
Green. Chem. Lett. Rev. 2, 23–27.
Thomas, A.B., Paradkar, O.D., Nanda, R.K., Tupe, P.N.,
Sharma, P.A., Badhe, R.V., Kothapalli, L.P., Banerjee, A.G.,
Hamane, S., Deshpande, A.D., 2010. Green Chem. Lett. Rev.
3, 293–300.
Tjolsen, A., Berge, O.G., Hunskaar, S., Rosland, J.H., Hole, K., 1992.
Pain 51, 5–17.
Vinger, R., Truax, J.F., Selph, J.L., Jonhston, P.R., Venable, A.L.,
McKenzie, K.K., 1987. Federation Proceedings 46, 118–126.
Wang, B., Gu, Y.L., Luo, G.Y., Yang, T., Yang, L.M., Suo, J.S., 2004.
Tetrahedron Lett. 45, 3369–3372.
Winter, C.A., Risley, E.A., Nuss, G.W., 1962. Proc. Soc. Exp. Biol.
Med. 11, 544–547.
